RAPT Therapeutics, Inc.
RAPT
$8.01
$0.689.28%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 28.37M | 28.88M | 27.33M | 27.78M | 27.81M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 122.85M | 136.10M | 114.85M | 128.98M | 128.02M |
Operating Income | -122.85M | -136.10M | -114.85M | -128.98M | -128.02M |
Income Before Tax | -116.51M | -129.87M | -107.49M | -120.43M | -118.05M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -116.51 | -129.87 | -107.49 | -120.43 | -118.05 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -116.51M | -129.87M | -107.49M | -120.43M | -118.05M |
EBIT | -122.85M | -136.10M | -114.85M | -128.98M | -128.02M |
EBITDA | -121.71M | -134.90M | -113.61M | -127.72M | -126.79M |
EPS Basic | -19.25 | -24.93 | -22.24 | -24.99 | -24.58 |
Normalized Basic EPS | -12.10 | -15.77 | -14.19 | -15.91 | -15.65 |
EPS Diluted | -19.25 | -24.93 | -22.24 | -24.99 | -24.58 |
Normalized Diluted EPS | -12.10 | -15.77 | -14.19 | -15.91 | -15.65 |
Average Basic Shares Outstanding | 42.48M | 20.39M | 19.35M | 19.28M | 19.21M |
Average Diluted Shares Outstanding | 42.48M | 20.39M | 19.35M | 19.28M | 19.21M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |